Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to determine whether NLRP3 inhibition with dapansutrile represents a
new pharmacological option for diabetes management with potential as an anti-inflammatory
agent to also address micro- and macro-vascular risk and complications from diabetes.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborators:
European Union (Horizon Europe Programme) Olatec Therapeutics LLC State Secretariat for Education Research and Innovation, Switzerland